Explore the details of the Array Biopharma Inc. V. Teva Pharmaceuticals, Inc. case under case number 1:23-cv-00625 involving a cause of action for Patent Infringement. Review key information about the parties involved, the patents in question, and the docket entries.

Case Details

Case Number
1:23-cv-00625
Filing Date
Jun 8, 2023
Cause of Action
Patent Infringement
Status
-
Nature of Suit
Patent - Abbreviated New Drug Application(ANDA)

The following parties are involved in this case, with their respective legal representatives for the case.

NameRepresented By
Teva Pharmaceuticals, Inc. -
Array BioPharma Inc. -

Patents Involved in the Case

This case involves 3 patents, each of which is central to the dispute. These patents may be subject to claims of infringement, challenges to their validity, or other issues concerning their scope and enforcement.

Application NumberPatent Number
-US9598376B2
-US9980944B2
-US9562016B2

Docket Entries

The Docket Entries section provides a chronological list of all significant filings and court actions in this case.

DateDocket EntryType

Set alerts for critical docket entry

Nov 8, 2024OPENING BRIEF in Support re 17 MOTION to Stay filed by Teva Pharmaceuticals, Inc..Answering Brief/Response due date per Local Rules is 11/22/2024. (DiBenedetto, Emily) (Entered: 11/08/2024)PACER Document
Nov 8, 2024MOTION to Stay - filed by Teva Pharmaceuticals, Inc.. (Attachments: # 1 Text of Proposed Order)(DiBenedetto, Emily) (Entered: 11/08/2024)PACER Document
Nov 22, 2024ANSWERING BRIEF in Opposition re 17 MOTION to Stay - filed by Array BioPharma Inc..Reply Brief due date per Local Rules is 12/2/2024. (Attachments: # 1 Exhibit A)(Dellinger, Megan) (Entered: 11/22/2024)PACER Document
Jun 14, 2023Case Assigned to Judge Gregory B. Williams. Please include the initials of the Judge (GBW) after the case number on all documents filed. (rjb)PACER Document
Jun 26, 2023SO ORDERED, re 8 STIPULATION TO EXTEND TIME to move, plead, or otherwise respond to the Complaint to August 4, 2023 filed by Teva Pharmaceuticals, Inc. Signed by Judge Gregory B. Williams on 6/26/2023. (etg)PACER Document
Aug 4, 2023SO ORDERED, re 9 MOTION for Pro Hac Vice Appearance of Attorney Daryl L. Wiesen, Alexandra D. Valenti, Gabriel Ferrante, and Christopher J. Cassella filed by Teva Pharmaceuticals, Inc. Signed by Judge Gregory B. Williams on 8/4/23. (ntl)PACER Document
Aug 8, 2023Pro Hac Vice Attorney Alexandra D. Valenti, Christopher J. Cassella, Daryl L. Wiesen, and Gabriel Ferrante for Teva Pharmaceuticals, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mkr)PACER Document
Sep 3, 2024ORAL ORDER: IT IS HEREBY ORDERED that, not later than thirty (30) days from the date of this Order, the parties shall meet and confer and file a joint proposed Scheduling Order in this action consistent with the applicable form Scheduling Order of Judge Williams, which is posted at http://www/ded/uscourts.gov (See Chambers, Judge Williams, Forms), along with a cover letter requesting the Court to enter the joint proposed Scheduling Order (if there are no disputes or other issues concerning scheduling that the Court needs to address) or to schedule the Rule 16 Scheduling Conference. If there are disputes or other issues the Court needs to address in the joint proposed Scheduling Order, in the cover letter, the parties shall direct the Court to the paragraph numbers in the joint proposed Scheduling Order which those appear. ORDERED by Judge Gregory B. Williams on 9/3/24. (jaa) (Entered: 09/03/2024)PACER Document
Oct 3, 2024SO ORDERED, re 14 STIPULATION TO EXTEND TIME for the parties to submit a proposed scheduling order to October 17, 2024 filed by Array BioPharma Inc.. Signed by Judge Gregory B. Williams on 10/3/24. (jaa)PACER Document
Oct 22, 2024ORAL ORDER: Having reviewed the parties' joint letter (D.I. 15) and given the Court's prior construction of the claim term "crystallized 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide" (i.e. "crystallized [binimetinib]") contained in U.S. Patent Nos. 9,562,016 ("the 016 Patent"), 9,598,376 ("the 376 Patent"), and 9,980,944 ("the 944 Patent") (collectively, the "Crystallized Binimetinib Patents") in Array's related litigation against Alembic Pharmaceuticals Limited and Sandoz Inc., Civil Action No. 22-1277-GBW, IT IS HEREBY ORDERED that any motion of any party in this action requesting to stay this case pending resolution of any appeal of the Court's claim construction of the same claim term ("crystallized [binimetinib]") in the same patents (the Crystallized Binimetinib Patents) in the related Alembic/Sandoz litigation, Civil Action No. 22-1277-GBW, should be made by formal motion or agreed to by stipulation and [proposed order] of the parties filed in this action on or before November 8, 2024. ORDERED by Judge Gregory B. Williams on 10/22/2024. (lnb) (Entered: 10/22/2024)PACER Document
Dec 2, 2024REPLY BRIEF re 17 MOTION to Stay filed by Teva Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A)(DiBenedetto, Emily) (Entered: 12/02/2024)PACER Document
May 22, 2025NOTICE of Withdrawal of Counsel by Array BioPharma Inc. (Dellinger, Megan) (Entered: 05/22/2025)PACER Document
Jun 8, 2023COMPLAINT filed against Teva Pharmaceuticals, Inc. ( Filing fee $ 402, receipt number ADEDC-4154119.) - filed by Array BioPharma Inc. (Attachments: # 1 Exhibit A, # 2 Civil Cover Sheet)(smg) (Entered: 06/08/2023)Attachment
Jun 8, 2023COMPLAINT filed against Teva Pharmaceuticals, Inc. ( Filing fee $ 402, receipt number ADEDC-4154119.) - filed by Array BioPharma Inc. (Attachments: # 1 Exhibit A, # 2 Civil Cover Sheet)(smg) (Entered: 06/08/2023)Attachment
Oct 17, 2024Letter to The Honorable Gregory B. Williams from Megan E. Dellinger regarding Plaintiff's Proposed Scheduling Order - re 13 Order,,,. (Attachments: # 1 Text of Proposed Order)(Dellinger, Megan) (Entered: 10/17/2024)Attachment
Nov 22, 2024ANSWERING BRIEF in Opposition re 17 MOTION to Stay - filed by Array BioPharma Inc..Reply Brief due date per Local Rules is 12/2/2024. (Attachments: # 1 Exhibit A)(Dellinger, Megan) (Entered: 11/22/2024)Attachment
Dec 2, 2024REPLY BRIEF re 17 MOTION to Stay filed by Teva Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A)(DiBenedetto, Emily) (Entered: 12/02/2024)Attachment